Boston Scientific (NYSE: BSX) reported earnings on July 25. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), Boston Scientific beat slightly on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue dropped slightly. Non-GAAP earnings per share expanded. GAAP earnings per share expanded.

Margins increased across the board.

Revenue details
 Boston Scientific reported revenue of $1.81 billion. The 20 analysts polled by S&P Capital IQ foresaw revenue of $1.78 billion on the same basis. GAAP reported sales were the same as the prior-year quarter's.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.12. The 21 earnings estimates compiled by S&P Capital IQ predicted $0.09 per share. Non-GAAP EPS of $0.12 for Q2 were 9.1% higher than the prior-year quarter's $0.11 per share. GAAP EPS were $0.10 for Q2 versus -$2.51 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 68.1%, 220 basis points better than the prior-year quarter. Operating margin was 13.7%, 20 basis points better than the prior-year quarter. Net margin was 7.2%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $1.71 billion. On the bottom line, the average EPS estimate is $0.09.

Next year's average estimate for revenue is $7.06 billion. The average EPS estimate is $0.41.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 752 members out of 937 rating the stock outperform, and 185 members rating it underperform. Among 192 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 175 give Boston Scientific a green thumbs-up, and 17 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Boston Scientific is hold, with an average price target of $9.17.

Is Boston Scientific the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.